Nocatee, Florida — State Attorney General James Uthmeier initiated a major antitrust case Tuesday against three global insulin manufacturers and three dominant pharmacy benefit managers, accusing them of coordinating a pricing structure that artificially escalated the cost of vital diabetes medications. Lodged in the Eleventh Judicial Circuit, the civil action names drug makers Sanofi, Eli Lilly, and Novo Nordisk, alongside major prescription processors OptumRx, CVS Caremark, and Express Scripts, as well as intermediary entities including Zinc, Emisar, and Ascent.
According to the complaint, drug producers systematically pushed up published list figures for insulin and related treatments while steering financial rebates and administrative fees back to benefit managers. State attorneys contend that this arrangement granted the medications favored placement on commercial formularies, creating a dynamic where both industry sectors gained revenue as benchmark prices rose. The filing notes that while insured customers often encounter lower negotiated sums, individuals subject to deductible phases, percentage-based coinsurance, or lack of insurance coverage are frequently compelled to pay full list prices.
State officials emphasized that approximately 2.3 million adult Floridians, representing roughly one out of every ten residents, live with a diabetes diagnosis. The litigation challenges pricing across traditional insulin formulations such as Humalog, as well as modern GLP-1 therapies and combination treatments including Soliqua, Ozempic, Victoza, and Trulicity. Under state law, the lawsuit asserts claims under Florida's Deceptive and Unfair Trade Practices Act alongside statutory antitrust provisions, pursuing permanent injunctive measures, financial restitution, disgorgement of revenue, and civil fines.
"These companies told Florida families they were working to make insulin affordable. Instead, they inflated the sticker price of a medicine people cannot live without and left Florida patients to pay it. My office is holding them accountable." — Florida Attorney General James Uthmeier
In northeast Florida, Nocatee is a planned community situated across northern St. Johns County and southern Duval County, roughly twenty miles south of downtown Jacksonville. Residents throughout the area rely on regional medical networks, community physicians, and local retail pharmacies for ongoing diabetes management and prescription refills.
